Rajarshi Banerjee


  • JD, cum laude, Harvard Law School, 2014; Board of Student Advisers
  • AB (Neurobiology), cum laude, Harvard College, 2011


  • Massachusetts, 2014
  • Bengali
  • Boston Bar Association
  • Homeless Empowerment Project

Rajarshi Banerjee


Raj helps life sciences companies and research institutions structure and negotiate licenses and collaborations. In addition, Raj advises venture-backed biotechnology companies from formation through initial public offering on equity financings, corporate governance issues, licenses, collaborations, and commercial agreements.


Life Sciences Transactions

  • Represents the Broad Institute of MIT and Harvard in connection with licenses and collaborations, including commercial and research tool licenses for CRISPR/Cas9.
  • Represented Sarepta Therapeutics in a strategic investment and licensing transaction with Lacerta Therapeutics, a gene therapy company, in which Sarepta entered into a license and option agreement for up to three new CNS-targeted gene therapy programs, including exclusive rights to Lacerta’s gene therapy candidate for Pompe Disease and options to two additional candidates, and made an equity investment of $30 million in Lacerta.
  • Represented Sarepta Therapeutics in connection with an exclusive license and collaboration agreement with Summit Therapeutics that extends Sarepta’s Duchenne muscular dystrophy drug pipeline.
  • Represents Juno Therapeutics in connection with supply and intellectual property license agreements.
  • Advised AMAG Pharmaceuticals in an agreement with Palatin Technologies to gain exclusive North American rights to develop and commercialize Rekynda™ (bremelanotide), valued at up to $465 million in upfront, milestone and ongoing development payments, plus tiered royalties on net sales.
  • Represented Janssen Pharmaceuticals in its $1.05 billion all-cash divestiture of U.S. license rights to the NUCYNTA® franchise of pharmaceutical products to Depomed, Inc.

Emerging Company Representation

  • Represents Compass Therapeutics, LogicBio Therapeutics and Vapotherm, among others, in venture financings and on corporate matters.


  • JD, cum laude, Harvard Law School, 2014; Board of Student Advisers
  • AB (Neurobiology), cum laude, Harvard College, 2011
Cookie Settings